BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul type="disc"><li>We are initiating coverage of PLx Pharma (PLXP) with a Buy Rating and $29 target.</li></ul> <ul type="disc"><li>PLXP is a combination of a management team with a successful launch history and a new drug delivery platform with its first FDA approved over the counter drug, aspirin without all the side effects.</li></ul> <ul type="disc"><li>PLXP launched VAZALORE, a recent FDA approved over the counter liquid filled aspirin, at the end of August in over 30 thousand retail pharmacy shelves.</li></ul> <ul type="disc"><li>The investment story has been de-risked from the beginning year. PLXP received FDA approval to begin commercialization of VAZALORE. PLXP has achieved product placement at major retailers at the onset of the product launch with preferred shelf placement at most stores.</li></ul> <ul type="disc"><li>PLXP should grow revenue steadily as consumer awareness for VAZALORE widens.</li></ul> <ul type="disc"><li>The achievement in removing the biggest barrier to taking aspirin could result in PLXP quickly becoming a target of a larger pharmaceutical company.</li></ul>

We are initiating coverage of PLx Pharma (PLXP) with a Buy Rating and $29 target. PLXP is a combination of a management team with a successful launch history and a new drug delivery platform with its first FDA approved over the counter drug, aspirin without all the side effects. PLXP launched VAZALORE, a recent FDA approved over the counter liquid filled aspirin, at the end of August in over 30 thousand retail pharmacy shelves. The investment story has been de-risked from the beginning year. PLXP received FDA approval to begin commercialization of VAZALORE. PLXP has achieved product placement at major retailers at the onset of the product launch with preferred shelf placement at most stores. PLXP should grow revenue steadily as consumer awareness for VAZALORE widens. The achievement in removing the biggest barrier to taking aspirin could result in PLXP quickly becoming a target of a larger pharmaceutical company.

PLXP: Band Back Together, Initiating with Buy